Area bioscience firm chasing vaccine raises $22 million

Tampa drugmaker also announced plans to redeem Series C preferred stock.

  • By Business Observer Staff
  • | 12:00 p.m. February 24, 2021
  • | 0 Free Articles Remaining!
Courtesy. Oragenics President and CEO Alan Joslyn
Courtesy. Oragenics President and CEO Alan Joslyn
  • Tampa Bay-Lakeland
  • Share

TAMPA — Oragenics Inc. has raised $22 million through the sale of common stock and by exercising warrants on its common stock, the company says.

The Tampa-based COVID-19 vaccine maker also announced that it has given notice to the holders of its Series C, non-convertible preferred stock that it intends to redeem those shares.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • December 18, 2025
Kolter, Casto buy 19 acres in Parrish
  • December 18, 2025
Tampa Museum of Art director to retire
  • December 18, 2025
ESPN report: Naples' Hoffmann family buying NHL hockey team
  • December 18, 2025
4-acre entertainment district to be built in downtown Tampa

Sponsored Content